Raja Fattaleh, MD
Family Medicine · Putnam, CTNPI 1841283439
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $38,066 of the $53,498 with a category attached, or 71.2%. It is spread thinly across 60 manufacturers, the largest accounting for just 17.3%. 2025 is the largest year on record at $19,564, 5.1 times the $3,816 reported in 2019. Among family medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,026 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$9K
- Lilly USA, LLC$7K
- AstraZeneca$4K
- AbbVie$4K
- Amgen$2K
- Novo Nordisk$2K
- plus $25K from 54 others
What the payments were for
- Consulting fees$6,64612%
- Speaking & faculty fees$6,90713%
- Travel & lodging$9112%
- Food & beverage$38,06671%
- Education$9692%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,498 in reported general payments places this provider in the 95th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 26 | $423,403 |
| SpravatoEsketamine Hcl | 234 | $283,762 |
| Humira(Cf) PenAdalimumab | 17 | $186,190 |
| IngrezzaValbenazine Tosylate | 17 | $182,879 |
| XareltoRivaroxaban | 154 | $150,973 |
| FarxigaDapagliflozin Propanediol | 126 | $144,430 |
| MounjaroTirzepatide | 117 | $137,442 |
| EliquisApixaban | 136 | $119,591 |
| CaplytaLumateperone Tosylate | 53 | $115,403 |
| ProliaDenosumab | 65 | $114,589 |
| Somatuline DepotLanreotide Acetate | 12 | $111,555 |
| JardianceEmpagliflozin | 99 | $106,419 |
| OzempicSemaglutide | 63 | $87,807 |
| ForteoTeriparatide | 16 | $79,705 |
| JanuviaSitagliptin Phosphate | 59 | $76,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Jardiance, Stiolto Respimat, Glyxambi, Spiriva Respimat | $1,675 | $658,642233 claims |
| Johnson & JohnsonSpravato, Xarelto | $1,475 | $434,735388 claims |
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $7,154 | $233,816149 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $4,428 | $203,201174 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $983 | $182,87917 claims |
| AmgenProlia, Otezla | $1,877 | $177,14878 claims |
| PfizerEliquis | $1,450 | $119,591136 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,414 | $115,40353 claims |
| AbbVieViberzi, Creon, Linzess, Vraylar | $3,546 | $114,24276 claims |
| MerckJanuvia, Janumet Xr | $371 | $88,53480 claims |
| Novo NordiskOzempic | $1,698 | $87,80763 claims |
| SanofiKevzara | $486 | $56,86413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Putnam
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Nicholas TzikasNew Haven$46K
- Helar CamposNew London$29K
- Kristin GianniniVernon$28K
- Sanjeev RaoBridgeport$27K
- Michael BeyVernon Rockville$27K
- Eric CamyreVernon$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.